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Introduction 
Several studies have shown that medication review improves the quality of 
pharmacotherapy.  There is no gold standard for the most effective type of 
medication review. We currently perform a randomised controlled clinical trial to 
investigate the effects of a clinical medication review that incorporates a patient 
home consultation (Home Medicines Review= HMR[1]). We now present baseline 
data aiming to investigate the number and types of drug-related problems (DRPs) 
identified by study pharmacists and independent pharmacist reviewers. Moreover 




Cross sectional study within a randomised controlled trial in a primary care setting.
Patients
Patients were recruited from ten Dutch community pharmacies. Patients were 
eligible if they were home-dwelling, aged 65 years and over and used five or 
more different drugs, including at least one cardiovascular or anti-diabetic drug. 
Consenting patients were visited at home as part of the intervention.
Intervention
The patient’s community pharmacist (=study pharmacist) visited the patient at 
home for an interview about the patient’s medicines and to identify possible 
drug related problems. A clinical medication review was performed by the study 
pharmacist. Medication reviews were evaluated, if necessary adjusted, and 
completed by an independent pharmacist reviewers panel. Potential drug related 
problems were discussed by the study pharmacist and patients’ general practitioner 
(GP). 
Main outcome measures
The primary outcome measures were: 1. the number of DRPs and recommendations 
identified by the study pharmacists and by the pharmacist reviewers 2. The number 
of DRPs identified by home consultations, pharmacy medication records, GP clinical 
records or combination of medication and clinical records.
Potential DRPs were classified using the D.O.C.U.M.E.N.T. classification[1]. 
Recommendations were divided in two main categories: involving a drug change 
and not involving a drug change (e.g. monitoring and patient education items).
Results
Data were collected for 147 intervention patients. The mean number of DRPs was 
9.9 per patient (see Table 1). The most common subtypes of DRPs  were “Condition 
not adequately treated”  and “Lack of indication or unclear indication”. 
5.4 recommendations per patient involved a drug change (see Table 2): most 
common recommendations were “Addition of a drug” and “Cessation of a drug”.
Study pharmacists identified 3.3 DRPs per patient (34%, see Table 1).  Study 
pharmacists identified relatively more items for DRP types “Compliance” and 
“Education and instruction”. 2.4 of the total number of 9.9 recommendations per 
patient (24%) were made by study pharmacists. 
26% of DRPs were identified during home consultations against 31% from 
medication records, 7% from clinical records and 35% from the combination of 
these two sources (see Table 3). Study pharmacists identified 1.1 DRPs per patient 
during home consultations. Pharmacist reviewers added 1.5 DRP per patient from 
the home consultation reports to be discussed with the GP.
Table 1: Frequency and type of drug-related problems (DRPs) identified 
by study pharmacists and pharmacist reviewers (classified with the 
D.O.C.U.M.E.N.T system).
Number of DRPs identified






Percent  of 
total by study 
pharmacists
D(rug Selection) 126 236 362 35%
Duplication 3 3 6
Drug interaction 6 9 15
Wrong dosage form 3 7 10
Lack of indication or unclear
indication
76 144 220
Lack of effectiveness 24 37 61
Contra-indication/ intolerance 14 36 50
O(ver or underdose) 45 85 130 35%
Dosage too high 12 15 27
Dosage too low 12 27 39
Dose frequency/schedule 21 43 64
C(ompliance) 38 31 69 55%
Taking too little 22 19 41
Taking too much 5 3 8
Difficulty using dosage form 11 9 20
U(ntreated conditions) 158 234 392 40%
Condition not adequately treated 142 207 349
Preventive therapy required 16 27 43
M(onitoring required) 61 275 336 18%
Laboratory monitoring 47 192 239
Non laboratory monitoring 14 83 97
E(ducation) or information 15 21 36 42%
Patient drug information request 1 2 3
Confusion about therapy 2 2 4
Demonstration of device 2 6 8
Disease management or advice 3 7 10
Other  education or information 
problem
7 4 11
T(oxicity) 43 80 123 35%
Toxicity evident 29 34 63
Risk on adverse effects 9 34 43
Possible drug treatment in 
response to adverse effect
5 12 17
Total (mean per patient) 486 (3.3) 962 (6.6) 1448 (9.9) 34%
Table 2: Frequency and type of recommendations identified by study 
pharmacists and pharmacist reviewers.







Percent  of 
total by study 
pharmacists
Involving a drug change
 Cessation of drug 47 127 174 27%
 Dose change 41 107 148 28%
 Addition of drug 76 168 244 31%
 Replacement of drug 38 98 136 28%
 Dose frequency/schedule change 19 50 69 28%
 Drug formulation change 9 12 21 43%
 Total (mean per patient) 230 (1.6) 562 (3.8) 792 (5.4) 29%
Not involving a drug change 
 Monitoring 58 278 336 17%
 Education 6 36 42 14%
 Other 53 225 278 19%
 Total (mean per patient) 117 (0.8) 539 (3.7) 656  (4.5) 18%
Total (mean per patient) 347 (2.4) 1101 (7.5) 1448 (9.9) 24%
Table 3: Contribution of the source of data to the identification of drug-related 
problems (DRPs) by study pharmacists and pharmacist reviewers
Number of DRPs identified (mean per 
patient) Percent 
contribution of 






Medication records 130 (0.9) 318 (2.2) 448 (3.0) 31%
Clinical records 34 (0.3) 63 (0.4) 97 (0.7) 7%
Medication and clinical records 160 (1.1) 353 (2.4) 513 (3.6) 35%
Home Consultation 162 (1.1) 221 (1.5) 383 (2.6) 26%
Total 486 (3.3) 962 (6.6) 1448 (9.9) 100%
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Conclusion
This study shows that the identification of DRPs in clinical medication reviews by 
study pharmacists in primary care can be improved. Patient home consultations 
have a major contribution in the identification of DRPs. Pharmacist reviewers 
identified more DRPs from the home consultation reports than study pharmacists.
